|
KMID : 1141720190070020094
|
|
폐쇄성폐질환
2019 Volume.7 No. 2 p.94 ~ p.98
|
|
|
Treatment of Severe Asthma: Anti-IgE or Anti-Eosinophils?
|
|
Song Woo-Jung
|
|
|
Abstract
|
|
|
|
Severe asthma is a serious medical condition. In addition to its direct impact on daily life, it also poses a substantial burden to future health outcomes. Patients with severe asthma are at a particularly high risk of developing medication side effects due to the high-intensity treatment requirements for controlling asthma activity. Importantly, the increased risks of systemic corticosteroids-induced complications are observed even at very low dose exposures. Newly developed T2 targeted biologics, including anti-IgE or anti-IL-5 therapies, may improve asthma control status and prevent future exacerbation, but also reduce the risk of corticosteroid-induced side effects in severe asthmatic patients with type 2 signatures. However, to date, there has been no direct comparison study to guide further precise indications for each biologic agent.
|
|
|
KEYWORD
|
|
|
Asthma, Severity, IgE, Eosinophils
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|